slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 43,171-43,200
Pages 10,126
Rows per page 30
Component
43,171-43,200 of 303,780
26
The scatter plot highlights a specific cluster of compounds selected by the AI that deviate from the standard Pareto front.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
27
The slide uses a small multiples approach to show dose-response curves across multiple patient samples, followed by a summary plot comparing the two groups over time.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
30
The slide features a 3D molecular visualization of the inhibitor.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
31
The slide outlines a standard clinical trial progression from dose escalation to expansion, with a focus on establishing RP2D and evaluating ORR.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
32
The slide uses a human anatomy diagram to map specific cancer types to their respective organ systems.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
33
Includes a biological pathway diagram and a honeycomb-style indication map.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
34
The slide uses a three-column layout to define the target product profile (TPP) criteria.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
35
The table uses a color-coded heatmap (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
36
The slide presents preclinical efficacy data for a CDK7 inhibitor ('617) in ovarian (OVCAR3) and triple-negative breast cancer (HCC70) models.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
37
The main chart is a waterfall plot showing drug response scores across many samples. The right side details translational findings and a combination testing framework.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
38
The slide uses a heatmap to visualize synergy (green) vs no synergy (light green) across different drug combinations and patient samples.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
39
Uses a Venn diagram to illustrate overlap between peripheral blood and tumour gene expression data.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
41
The slide uses a bar chart to demonstrate efficacy at lower doses compared to a failed large pharma drug.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
42
The slide uses a heatmap-style table to visualize performance metrics, highlighting the competitive advantage of the company's lead asset.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
43
The slide outlines a workflow from experimental data collection to AI-driven design and final compound nomination.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
44
The background features a 3D molecular visualization, likely representing the LSD1 protein or the drug binding to it.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
45
The slide uses a human anatomy diagram to map specific patient counts to disease locations.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
46
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
47
Includes two scientific citations for the mechanism and brain penetration.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
48
The slide uses a three-column layout to define the technical requirements for a drug candidate.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
49
The slide uses a color-coded heatmap to visualize performance against a Target Product Profile (TPP).Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
50
The slide uses a linear process flow to explain a complex computational chemistry workflow.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
51
The chart uses a Pareto front to illustrate the trade-off between CNS score and Potency, highlighting that the 'best' molecules are not always the most information-rich.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
52
Includes statistical significance markers (*) on the tumour volume chart.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
53
The slide uses two distinct chart types (dot plot and line chart) to demonstrate safety profiles.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
54
The chart shows tumour volume over time for various dosing regimens compared to a vehicle control.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
55
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
56
The slide uses a split-layout to contrast current operational status with overall program value proposition.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
58
The slide uses a three-column layout to summarize the value proposition of the drug candidate.Exscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits
59
Exscientia | Investor Presentation Deck | 69 slidesExscientia | Investor Presentation Deck | 69 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Golden Circle2 hits